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Association between Open-
Angle Glaucoma and the Risks 
of Alzheimer’s and Parkinson’s 
Diseases in South Korea: A 10-year 
Nationwide Cohort Study
Jong Youn Moon1,2, Hyung Jun Kim3, Yoon Hyung Park1, Tae Kwann Park4, Eun-Cheol Park  2, 
Chan Yun Kim5 & Si Hyung Lee4
We aimed to investigate the risks of Alzheimer’s (AD) and Parkinson’s disease (PD) in the 10 years 
following diagnosis of open-angle glaucoma (OAG) using a nationwide cohort. This propensity score-
matched retrospective cohort study included 1,025,340 subjects from the Korean National Health 
Insurance Service National Sample Cohort database. The OAG group (n = 1,469) included patients 
who were initially diagnosed with OAG between 2004 and 2007, and the subjects in the comparison 
group were matched in a 1:5 ratio using propensity scores. Cox regression analyses were performed to 
investigate the risks of developing AD or PD. The diagnosis of OAG was significantly associated with 
an increased incidence of AD (hazard ratio [HR] = 1.403, 95% confidence interval [CI] 1.180–1.669, 
p < 0.001), but not PD (HR = 0.995, 95% CI 0.620–1.595, p = 0.983) after adjusting for possible 
confounding factors. In subgroup analyses, participants with OAG aged ≥65 years were more likely 
to develop AD compared with those aged <65 years, and female OAG patients had a greater risk of 
developing AD than males. Patients diagnosed with OAG have a higher risk of developing AD, but not 
PD, and the risk differed according to age and sex.
Open-angle glaucoma (OAG) is a leading cause of irreversible blindness and is characterized by chronic progres-
sive glaucomatous optic neuropathy with corresponding visual field defects1,2. Retinal ganglion cells (RGCs), the 
main target of glaucomatous damage, are central nervous system neurons located in the inner layer of the retina 
that convey information from the retina to the brain. On developing glaucoma, injuries occur in optic nerve 
axons, leading to progression of RGC neurodegeneration3,4. It is widely accepted that intraocular pressure (IOP) 
plays a crucial role in the development and progression of OAG, and several non-IOP factors have been reported 
to be associated with OAG pathogenesis5–8. However, there are still many mysteries to unravel to determine the 
mechanisms involved in RGC damage in glaucoma patients.
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common neurodegenerative dis-
orders in the elderly9. In AD, neurons and synapses are lost in the cerebral cortex, in the presence of extracel-
lular amyloid-β plaques (Aβ) and neurofibrillary tangles that consist of phosphorylated Tau protein, leading to 
progressive memory loss, behavioral disturbances, personality changes, and cognitive impairment10,11. PD is a 
chronic, progressive movement disorder in which patients show slow movement, difficulty walking, rigidity, and 
tremor, caused by the loss of dopaminergic neurons in the substantia nigra12,13. It is related to alpha-synuclein, the 
major biochemical component of Lewy bodies14. Neurodegenerative disease, i.e., the progressive loss of neuron 
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structure or function, including AD and PD, is currently recognized as a major public health issue with the aging 
global population15,16. There is increasing evidence of neurodegenerative lesions found in AD are also observed 
in the optic nerve, lateral geniculate nucleus, and visual cortex in glaucoma patients, suggesting that OAG is a 
neurodegenerative disease of the eye17–24. Previous experimental and clinical studies have shown close associa-
tions between OAG and PD25–27. These two neurodegenerative diseases, AD and PD, and glaucoma share several 
biological features, such as being chronic, slowly progressive disorders with an age-related incidence and similar 
mechanisms of cell injury. Although there are strong associations between OAG and AD or PD, only a few epide-
miological studies have been conducted with inconsistent results, leaving the relationship between the conditions 
inconclusive28–33.
In light of this, we investigated the risks of developing AD and PD after an initial diagnosis of OAG, and 
compared the risk of each neurodegenerative disease during the 10 years following diagnosis of OAG using 
a representative South Korean sample of approximately 1 million adults from the National Health Insurance 
Service-National Sample Cohort 2002–2013 (NHIS-NSC 2002–2013).
Results
Table 1 shows the baseline characteristics of the study population. The study ultimately enrolled 1,469 patients 
with OAG and 7,345 individuals for the comparison group. There was a significant difference in AD prevalence 
between the OAG group and the comparison group (p < 0.001). Hypertension (p < 0.001), diabetes mellitus 
(p < 0.001), hyperlipidemia (p < 0.001), and ischemic stroke (p = 0.003) were more prevalent in the OAG group 
than in the comparison group. There were no significant differences in the other parameters used for matching, 
which included sex, age group, income, residential area, Charlson comorbidity index (CCI), and the year of 
enrollment. When subjects were grouped according to the diagnosis of each neurodegenerative disease, subse-
quent AD developed in 742 subjects and subsequent PD developed in 118 subjects during the median follow-up 
period of 6.99 years. Subjects with AD and PD had higher proportions of female, old age, high income, and high 
CCI than patients without these diseases (Table 2).
The risk of developing subsequent AD or PD during the 10-year follow-up period was evaluated using multi-
variate Cox hazard regression analyses with three different models, crude model, model 1 hypertension, diabetes 
mellitus, hyperlipidemia and ischemic stroke) and model 2 (adjusted for age, sex, residential area, income, CCI, 
hypertension, diabetes mellitus, hyperlipidemia and ischemic stroke). All three models revealed that the risk of 
developing subsequent AD during the 10-year follow-up period was significantly higher in the OAG group than 
in the comparison group (Crude: hazard ratio [HR] = 1.623, 95% confidence interval [CI] 1.369–1.924, p < 0.001; 
model 1: HR = 1.421, 95% CI 1.199–1.684, p < 0.001; model 2: HR = 1.403, 95% CI 1.180–1.669, p < 0.001) 
(Table 3). In model 1, hypertension, diabetes mellitus, ischemic stroke were also associated with an increased risk 
of AD development (Supplementary Table 1), while in model 2, old age, female gender, ischemic stroke and a high 
CCI score were significantly associated with an increased risk of developing AD (Supplementary Table 2). In com-
parison, the risk of developing PD in the OAG group was not significant compared with the comparison group in 
all three models (Crude: HR = 1.115, 95% CI 0.696–1.788, p = 0.650; model 1: HR = 0.984, 95% CI 0.612–1.582, 
p = 0.946; model 2: HR = 0.995, 95% CI 0.620–1.595, p = 0.983), and there were disparities in the development of 
PD according to hypertension and ischemic stroke in model 1, and ischemic stroke and subject age in model 2. 
(Supplementary Tables 1 and 2).
The Kaplan–Meier survival curves showed that the risk of developing AD among OAG patients was higher 
than in the comparison group (log-rank test, p < 0.001, (Fig. 1a), whereas no significant difference in the cumu-
lative PD incidence was observed between the OAG and comparison groups (log-rank test, p = 0.414, Fig. 1b).
The incidence of AD per 1,000 person-years for the OAG and comparison groups was 38.2% and 46.2%, 
respectively (Fig. 2). In subgroup analyses based on multivariate Cox regression, the adjusted HR of AD in the 
OAG patients with diabetes mellitus was greater (HR = 1.535) than that in the subjects without diabetes mellitus 
(HR = 1.097). The risk of developing AD in the OAG group was higher in those with hyperlipidemia or ischemic 
stroke (HR = 1.585 and HR = 1.511, respectively) compared with those without hyperlipidemia or ischemic 
stroke (HR = 0.881 and HR = 1.344, respectively). The risk of developing AD in patients with OAG was higher in 
the older subgroup (age ≥ 65 years; HR = 1.745) than that in the younger subgroup (age < 65 years; HR = 1.167). 
Subgroups for hypertension and sex had a similar HR to that of the entire cohort regardless of the presence of the 
disease or gender.
Discussion
Many studies have suggested that glaucoma is an age-related neurodegenerative disease, sharing many features of 
other well-known neurodegenerative diseases. The relationships between neurodegenerative diseases and glau-
coma have been widely investigated, showing positive relationships between the disorders. However, there are still 
conflicting results regarding whether glaucoma is a risk factor for the development of neurodegenerative disor-
ders. In this study, using longitudinal data from a nationwide cohort, we demonstrated an increased risk of neu-
rodegenerative disease development in OAG patients during a 10-year follow-up period compared with a control 
group. Subgroup analyses revealed that primary OAG patients had a significantly higher risk of developing AD, 
whereas a non-significant association was found for PD. The relationship between AD and OAG was stronger in 
older patients. There was no significant (p = 0.222) difference in patients younger than 60 years; in patients over 
70 years old, the relationship was stronger than in younger patients and the statistical significance was increased 
(HR = 2.614, p < 0.001). To our knowledge, this is the first nationwide population-based cohort study from South 
Korea on the association between OAG and the risk of AD and PD.
Experimental and clinical studies have demonstrated a strong link between AD and primary OAG. While 
the presence of extracellular Aβ plaques and neurofibrillary tangles consisting of phosphorylated Tau protein is 
a characteristic feature of AD, many experimental studies have revealed increased levels of Aβ and Tau protein 
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in vivo and in vitro. A recent study showed an increased Aβ level in the optic nerve and RGC layer in glaucoma-
tous animal models21,22, and tauopathy was also detected in the glaucomatous retina23. A recent study observed 
these AD-like pathologies in the lateral geniculate nucleus and primary visual cortex in a chronic hypertensive 
glaucoma monkey model24. However, the results of epidemiological studies are still conflicting. Retrospective 
registry-based studies conducted in Denmark and the United States found no increased risk of developing AD 
in OAG patients30,31,34. Conversely, other studies found a positive correlation between AD and OAG and found 
that patients with AD had a higher prevalence of OAG than controls35,36. In recent studies from Taiwan, patients 
with OAG had a 1.5-fold increased chance of AD37, and the prevalence of AD in OAG patients was higher than 
in the control group, implying that OAG is a significant predictor of AD in elderly patients29. Our findings from 
Patient without OAG Patient with OAG
P-value
Total
N % N % N
Total 7,345 100.0% 1,469 100.0% 8,814
Presence of AD or PD
No 6,682 91.0% 1,272 86.6% <0.001 7,954
AD 567 7.7% 175 11.9% 742
PD 96 1.3% 22 1.5% 118
Hypertension
No 2,615 35.6% 446 30.4% <0.001 3,061
Yes 4,730 64.4% 1,023 69.6% 5,753
Diabetes
No 3,112 42.4% 539 36.7% <0.001 3,651
Yes 4,233 57.6% 930 63.3% 5,163
Hyperlipidemia
No 2,582 35.2% 429 29.2% <0.001 3,011
Yes 4,763 64.8% 1,040 70.8% 5,803
Ischemic stroke
No 5,836 79.5% 1,117 76.0% 0.003 6,953
Yes 1,509 20.5% 352 24.0% 1,861
Variables for matching
Sex
Male 3,886 52.9% 781 53.2% 0.856 4,667
Female 3,459 47.1% 688 46.8% 4,147
Age group
≤49 1,852 25.2% 372 25.3% 0.958 2,224
50–59 1,447 19.7% 287 19.6% 1,734
60–69 2,239 30.5% 436 29.7% 2,675
70–79 1,477 20.1% 306 20.8% 1,783
≥80 330 4.5% 68 4.6% 398
Income
High 3,861 52.6% 759 51.7% 0.684 4,620
Milddle 2,142 29.2% 428 29.1% 2,570
Low 1,342 18.3% 282 19.2% 1,624
Residential area
Metropolitan 514 7.0% 106 7.2% 0.944 620
City 3,299 44.9% 655 44.6% 3,954
Rural 3,532 48.1% 708 48.2% 4,240
CCI
≤3 5,891 80.2% 1,176 80.1% 0.895 7,067
>3 1,454 19.8% 293 19.9% 1,747
Year
2004 1,435 19.5% 287 19.5% 1.000 1,722
2005 1,495 20.4% 299 20.4% 1,794
2006 1,395 19.0% 279 19.0% 1,674
2007 1,355 18.4% 271 18.4% 1,626
2008 1,665 22.7% 333 22.7% 1,998
Table 1. Demographic characteristics of study population. OAG = open angle glaucoma; AD = Alzheimer’s 
disease; PD = Parkinson’s disease; CCI = Charlson comorbidity index.
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the Korean population are consistent with these studies supporting the significant relationship between primary 
OAG and subsequent AD development.
PD is a long-term neurodegenerative disease of the central nervous system that mainly affects the motor 
system13 and is the second most common neurodegenerative disease after AD, affecting approximately seven 
million people globally9. Previously, abnormalities in visual function have been reported in PD patients25 and 
numerous studies have reported changes in the retinal nerve fiber layer thickness26. One study found that patients 
with PD had a higher prevalence of OAG27. Subsequently, two studies examined whether primary OAG is an 
early manifestation of PD: one found a small correlation but a significant increase in the risk of PD (adjusted 
HR = 1.23)38, and the other found that the prevalence of PD did not increase in OAG patients29. In this study, 
we also examined whether OAG is an early manifestation of PD in Koreans, but found no evidence for this. AD 
and PD share neuroinflammation as a common pathogenic mechanism and the retina is an extension of the 
brain. Therefore, the neuroinflammatory response in the brain may also occur in the retina and may lead to the 
Patients without AD 
or PD AD PD Total
Total 7954 (90.2%) 742 (8.4%) 118 (1.3%) 8,814
OAG
No 6,682 (84.0%) 567 (76.4%) 96 (81.4%) 7,345
Yes 1,272 (16.0%) 175 (23.6%) 22 (18.6%) 1,469
Hypertension
No 2,988 (37.6%) 62 (8.4%) 11 (9.3%) 3,061
Yes 4,966 (62.4%) 680 (91.6%) 107 (90.7%) 5,753
Diabetes
No 3,506 (44.1%) 119 (16.0%) 26 (22.0%) 3,651
Yes 4,448 (55.9%) 623 (84.0%) 92 (78.0%) 5,163
Hyperlipidemia
No 2,873 (36.1%) 114 (15.4%) 24 (20.3%) 3,011
Yes 5,081 (63.9%) 628 (84.6%) 94 (79.7%) 5,803
Ischemic stroke
No 6,620 (83.2%) 279 (37.6%) 54 (45.8%) 6,953
Yes 1,334 (16.8%) 463 (62.4%) 64 (54.2%) 1,861
Variables for matching
Sex
Male 4,298 (54.0%) 318 (42.9%) 51 (43.2%) 4,667
Female 3,656 (46.0%) 424 (57.1%) 67 (56.8%) 4,147
Age group
≤49 2,221 (27.9%) 1 (0.1%) 2 (1.7%) 2,224
50–59 1,690 (21.3%) 36 (4.9%) 8 (6.8%) 1,734
60–69 2,423 (30.5%) 201 (27.1%) 51 (43.2%) 2,675
70–79 1,337 (16.8%) 399 (53.8%) 47 (39.8%) 1,783
≥80 283 (3.6%) 105 (14.2%) 10 (8.5%) 398
Income
High 4,095 (51.5%) 452 (60.9%) 73 (61.9%) 4,620
Milddle 2,395 (30.1%) 150 (20.2%) 25 (21.2%) 2,570
Low 1,464 (18.4%) 140 (18.9%) 20 (16.9%) 1,624
Residential area
Metropolitan 558 (7.0%) 58 (7.8%) 4 (3.4%) 620
City 3,597 (45.2%) 304 (41.0%) 53 (44.9%) 3,954
Rural 3,799 (47.8%) 380 (51.2%) 61 (51.7%) 4,240
CCI
≤3 6,655 (83.7%) 350 (47.2%) 62 (52.5%) 7,067
>3 1,299 (16.3%) 392 (52.8%) 56 (47.5%) 1,747
Year
2004 1,524 (19.2%) 173 (23.3%) 25 (21.2%) 1,722
2005 1,594 (20.0%) 177 (23.9%) 23 (19.5%) 1,794
2006 1,524 (19.2%) 128 (17.3%) 22 (18.6%) 1,674
2007 1,483 (18.6%) 121 (16.3%) 22 (18.6%) 1,626
2008 1,829 (23.0%) 143 (19.3%) 26 (22.0%) 1,998
Table 2. Characteristics according to the presence of Alzheimer’s disease or Parkinson’s disease. OAG = open 
angle glaucoma; AD = Alzheimer’s disease; PD = Parkinson’s disease; CCI = Charlson comorbidity index.
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development of glaucoma39. However, these diseases are caused by the deposition of different protein aggregates 
in specific anatomical areas and neuronal cell death in one or more populations of neurons. In AD, beta-amyloid 
and neurofibrillary tangles consisting of phosphorylated Tau protein accumulate in the hippocampal and cortical 
neurons, while in PD, Lewy bodies consisting of alpha-synuclein accumulate in the nigrostriatal neurons14,39. 
These pathogenic differences may have caused the discordant results in the AD and PD groups in our study. 
Additional studies are needed to address this issue.
The results of our subgroup analyses suggested particular associations between AD and OAG, which, to our 
knowledge, have not been reported. In the OAG group, the risk of developing AD during the 10-year period 
was higher in OAG patients older than 65 years of age compared with those younger than 65 years of age. This 
relationship implies that the two disorders are mainly related to the neurodegeneration associated with aging. 
There were also different associations for males and females, with female OAG patients having a greater risk 
Outcome
Crude Model 11 Model 22
Hazard ratio (95% 
CI) p-value
Hazard ratio (95% 
CI) p-value
Hazard ratio (95% 
CI) p-value
AD
No OAG 1.000 (reference) 1.000 (reference) 1.000 (reference)
OAG 1.623 (1.369–1.924) <0.001 1.421 (1.199–1.684) <0.001 1.403 (1.180–1.669) <0.001
PD
No OAG 1.000 (reference) 1.000 (reference) 1.000 (reference)
OAG 1.115 (0.696–1.788) 0.650 0.984 (0.612–1.582) 0.946 0.995 (0.620–1.595) 0.983
Table 3. Hazard ratios for Alzheimer’s disease or Parkinson’s disease in multivariable Cox regression analysis. 
1Adjusted for hypertension, diabetes mellitus, hyperlipidemia and ischemic stroke. 2Adjusted for age, sex, 
residential area, income, Charlson comorbidity index, hypertension, diabetes mellitus, hyperlipidemia and 
ischemic stroke. OAG = open angle glaucoma; AD = Alzheimer’s disease; PD = Parkinson’s disease.
Figure 1. Cumulative hazards of (a) Alzheimer’s disease and (b) Parkinson’s disease.
Figure 2. Subgroup analysis of Alzheimer’s disease based on multivariate Cox regression.
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of developing AD than male patients. This was consistent with a report that not only was OAG more prevalent 
in women but also that the incidence of AD was higher in elderly women than in men40,41. Moreover, OAG 
patients with diabetes mellitus or hyperlipidemia had higher risks of developing AD. Although still controversial, 
numerous studies have identified diabetes mellitus and hyperlipidemia as risk factors for both OAG and AD7,42–45. 
Conversely, metformin and statins, which are the most prescribed medications for diabetes mellitus and hyper-
lipidemia, respectively, have shown protective effects on the neurodegenerative changes in both glaucoma and 
AD46–49, making it more difficult to conclude the exact relationships between the two comorbidities and OAG or 
AD. Hypertension and ischemic stroke are also related to either OAG or AD44,50–52, although we found similar HR 
values for the subgroups with or without hypertension or ischemic stroke.
There are several limitations to consider when interpreting our results. First, due to the inherent nature of the 
data used in our analyses, the diagnoses of OAG, AD, PD, and other comorbidities were based entirely on the 
KCD code system, and may be less accurate than diagnoses obtained through a standardized diagnostic process. 
To ensure the diagnosis of OAG, we included those who satisfied three inclusion criteria as OAG patients: the 
diagnostic code for OAG; the code for visual field tests; and prescriptions of antiglaucoma drugs. We believe that 
the OAG subjects included in our study had high specificity. Second, it is possible that the OAG patients may 
have been underestimated because the data are based on hospital visits. The data do not include initial patients 
who did not experience symptoms and patients who do not visit the hospital for economic reasons. However, the 
degree of underestimation is limited, due to the low cost and high accessibility of the Korean medical system, a 
government-run healthcare system including nearly the entire population of South Korea. Therefore, it is unlikely 
that inaccuracy and underestimation of the diagnosis affected the statistical results. Third, our data include only 
data for the Korean population, and there may be differences in other ethnic groups. Studies from Asian ethnicity 
have reported a positive association between OAG and AD28,29,37. By contrast, studies conducted in Denmark, the 
United Kingdom, and the United States showed that this was not relevant30,32,34. Further studies are required to 
reveal specific differences in different ethnic groups.
In conclusion, this 10-year nationwide cohort study demonstrated that OAG was associated with an increased 
risk of developing AD compared with the risk in the general population. However, there was no positive associ-
ation between OAG and PD. In addition, OAG patients older than 65 years of age or female OAG patients were 
more likely to develop AD than those under 65 years of age or male OAG patients. The results of this study have 
clinical implication on current understandings on OAG and further add to the evidences that OAG is a type of 
neurodegenerative disease. OAG patients should be followed closely for the subsequent development of symp-
toms related to AD, with neurological examinations for an early diagnosis of AD.
Methods and Materials
Database and study sample. We used data from the NHIS-NSC 2002–2013. The Korean National Health 
Insurance Service (KNHIS) is a mandatory single medical insurer system that provides universal healthcare cov-
erage in the Republic of Korea, and all citizens are obligated to enroll in the system. The KNHIS developed the 
National Health Information Database (NHID), which contains personal demographic records to collect insurance 
premium and subscription data for reimbursement. The NHIS-NSC sampled 1,025,340 individuals from among 
46,605,433 individuals in the NHID in 2002 and followed them until 201353. The study design was approved by 
the Institutional Review Board of Soonchunhyang University Bucheon Hospital, Gyeonggi-do, Korea. This study 
adhered to the tenets of the Declaration of Helsinki, and the need for written informed consent was waived.
Selection of glaucoma cases and controls. The index OAG cases were defined as patients who met all 
three of the following criteria: (1) diagnosed with primary OAG (Korean Classification of Diseases [KCD] code 
H401) as the main diagnosis code; (2) having a visual field test code (E6691); and (3) prescribed glaucoma medica-
tion. To exclude chronic OAG patients, we included patients who were diagnosed with OAG from 2004 to 2008. As a 
result, there were 1,587 index OAG cases. We excluded 118 patients who were diagnosed with AD (KCD codes F009, 
G300, G301, G308, and G309) or PD (code G20) before the OAG diagnosis, and ultimately enrolled 1,469 subjects.
Control subjects were selected from individuals who did not meet the OAG case criteria each year in a 1:5 
ratio to glaucoma patients using propensity score with nearest neighbor matching54. Ultimately, 7,345 control 
subjects were included. Propensity scores were calculated using sociodemographic parameters, including age 
group (≤49, 50–59, 60–69, 70–79, ≥80), sex, income (≤40th, 41st–70th, ≥71st percentiles), residential area (urban, 
metropolitan cities, and cities, rural, all other areas), and Charlson comorbidity index (CCI; score <3, ≥3). We 
used the CCI to determine whether the subject visited medical facilities frequently55.
Outcomes and comorbidities. In the matched populations, we compared the incidence of AD and PD. 
Comorbid conditions included hypertension (codes I10–I15), diabetes (codes E10–E14), hyperlipidemia (codes 
E78.0–E78.5), and ischemic stroke (code I61) that were diagnosed between 2002 and 2008.
Statistical analysis. The baseline characteristics are shown as the mean and standard deviation or num-
ber and percentage. The chi-square test was used to compare the groups. Multivariate Cox proportional hazard 
regression analysis was performed to calculate the HR with the 95% confidence interval (CI) for estimating the 
incidence of AD or PD in the OAG patients. Three models were used to demonstrate HRs for developing subse-
quent AD or PD, which included crude model, minimal adjusted model 1 (adjusted for hypertension, diabetes 
mellitus, hyperlipidemia and ischemic stroke) and fully adjusted model 2 (adjusted for age, sex, residential area, 
income, CCI, hypertension, diabetes mellitus, hyperlipidemia and ischemic stroke). Subgroup analyses were con-
ducted for age group (≥65 and <65), sex, and comorbidities. Survival curves for developing AD or PD were 
generated. All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA) and R 3.4.1 (R 
Project for Statistical Computing, Vienna, Austria).
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